NASDAQ:AERI Aerie Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aerie Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $8.36 +0.86 (+11.47%) (As of 07/1/2022 12:00 AM ET) Add Compare Share Today's Range$7.41▼$8.4250-Day Range$4.95▼$8.3652-Week Range$4.81▼$17.21Volume641,192 shsAverage Volume788,696 shsMarket Capitalization$406.49 millionP/E RatioN/ADividend YieldN/APrice Target$20.78 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Aerie Pharmaceuticals Stock Forecast (MarketRank)Analyst RatingModerate Buy2.75 Rating ScoreUpside/Downside148.5% Upside$20.78 Price TargetShort InterestHealthy8.11% of Float Sold ShortDividend StrengthN/ASustainability-3.03Upright™ Environmental ScoreNews Sentiment0.66Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.21) to ($1.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.92 out of 5 starsMedical Sector649th out of 1,429 stocksBiological Products, Except Diagnostic Industry105th out of 217 stocks 3.4 Analyst's Opinion Consensus RatingAerie Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.78, Aerie Pharmaceuticals has a forecasted upside of 148.5% from its current price of $8.36.Amount of Analyst CoverageAerie Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.11% of the float of Aerie Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAerie Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Aerie Pharmaceuticals has recently decreased by 19.01%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAerie Pharmaceuticals does not currently pay a dividend.Dividend GrowthAerie Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAerie Pharmaceuticals has received a 49.06% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Netarsudil", "Latanoprost", and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Aerie Pharmaceuticals is -3.03. Previous Next 2.0 News and Social Media Coverage News SentimentAerie Pharmaceuticals has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aerie Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for AERI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aerie Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aerie Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.34% of the stock of Aerie Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aerie Pharmaceuticals are expected to grow in the coming year, from ($2.21) to ($1.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aerie Pharmaceuticals is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aerie Pharmaceuticals is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AERI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address About Aerie Pharmaceuticals (NASDAQ:AERI)Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.Read More AERI Stock News HeadlinesJuly 1, 2022 | americanbankingnews.comAerie Pharmaceuticals (NASDAQ:AERI) Lifted to Buy at StockNews.comJune 22, 2022 | americanbankingnews.comStockNews.com Downgrades Aerie Pharmaceuticals (NASDAQ:AERI) to HoldJune 18, 2022 | americanbankingnews.comComparing Aerie Pharmaceuticals (NASDAQ:AERI) & Genfit (NASDAQ:GNFT)June 11, 2022 | americanbankingnews.comAerie Pharmaceuticals (NASDAQ:AERI) Upgraded to Buy at StockNews.comMay 25, 2022 | finance.yahoo.comAerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ETMay 24, 2022 | markets.businessinsider.comAerie Pharmaceuticals Begins Patient Dosing In Late-Stage Dry Eye Disease StudyMay 24, 2022 | seekingalpha.comAerie Pharmaceuticals begins dosing in late-stage study of AR-15512 for dry eye diseaseMay 24, 2022 | finance.yahoo.comAerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye DiseaseMay 9, 2022 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Aerie Pharmaceuticals: Here's What You Need To KnowMay 7, 2022 | seekingalpha.comAerie Pharmaceuticals' (AERI) CEO Raj Kannan on Q1 2022 Results - Earnings Call TranscriptMay 7, 2022 | finance.yahoo.comFurther weakness as Aerie Pharmaceuticals (NASDAQ:AERI) drops 12% this week, taking three-year losses to 85%May 6, 2022 | finance.yahoo.comAerie (AERI) Q1 Loss Wider Than Expected, Revenues Rise Y/YMay 5, 2022 | finance.yahoo.comAerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business UpdateSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AERI CUSIPN/A CIK1337553 Webwww.aeriepharma.com Phone(919) 237-5300Fax949-526-8787Employees376Year FoundedN/ACompany Calendar Last Earnings5/05/2022Today7/02/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$20.78 High Stock Price Forecast$29.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+148.5%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74.81 million Net Margins-34.20% Pretax Margin-33.57% Return on EquityN/A Return on Assets-11.30% Debt Debt-to-Equity RatioN/A Current Ratio2.75 Quick Ratio2.40 Sales & Book Value Annual Sales$194.13 million Price / Sales2.09 Cash FlowN/A Price / Cash FlowN/A Book Value($0.37) per share Price / Book-22.59Miscellaneous Outstanding Shares48,623,000Free Float43,595,000Market Cap$406.49 million OptionableOptionable Beta0.75 Aerie Pharmaceuticals Frequently Asked Questions Should I buy or sell Aerie Pharmaceuticals stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aerie Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" Aerie Pharmaceuticals stock. View analyst ratings for Aerie Pharmaceuticals or view top-rated stocks. What is Aerie Pharmaceuticals' stock price forecast for 2022? 4 analysts have issued twelve-month price targets for Aerie Pharmaceuticals' shares. Their AERI stock forecasts range from $13.00 to $29.00. On average, they anticipate Aerie Pharmaceuticals' stock price to reach $20.78 in the next year. This suggests a possible upside of 148.5% from the stock's current price. View analysts' price targets for Aerie Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Aerie Pharmaceuticals' stock performed in 2022? Aerie Pharmaceuticals' stock was trading at $7.02 at the start of the year. Since then, AERI shares have increased by 19.1% and is now trading at $8.36. View the best growth stocks for 2022 here. When is Aerie Pharmaceuticals' next earnings date? Aerie Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for Aerie Pharmaceuticals. How were Aerie Pharmaceuticals' earnings last quarter? Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) issued its quarterly earnings data on Thursday, May, 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by $0.01. The business earned $29.84 million during the quarter, compared to analysts' expectations of $30.19 million. During the same quarter in the previous year, the company posted ($0.72) EPS. View Aerie Pharmaceuticals' earnings history. Who are Aerie Pharmaceuticals' key executives? Aerie Pharmaceuticals' management team includes the following people: Mr. Raj Kannan, CEO, Principal Financial Officer & Director (Age 58, Pay $753.49k)Dr. Casey C. Kopczynski Ph.D., Co-Founder, Chief Innovation Officer & Head of Research and External Innovation (Age 61, Pay $685.06k)Mr. John W. LaRocca Esq., Gen. Counsel & Sec. (Age 57, Pay $676.62k)Mr. Peter F. Lang, Chief Financial Officer (Age 50)Dr. Michelle Senchyna Ph.D., Head of Clinical Devel. & OperationsMr. Jeffrey M. Calabrese CPA, VP of Fin. & Principal Accounting Officer (Age 55)Ms. Carolyn McAuliffe, Sr. Director of CommunicationsMs. Wanda Francies, Head of HRMr. Marvin J. Garrett, Head of Regulatory Affairs & Quality Assurance (Age 71)Mr. Craig R. Skenes, Head of Bus. Devel. Who are some of Aerie Pharmaceuticals' key competitors? Some companies that are related to Aerie Pharmaceuticals include ImmunityBio (IBRX), Revolution Medicines (RVMD), Recursion Pharmaceuticals (RXRX), Exscientia (EXAI), SpringWorks Therapeutics (SWTX), Vaxcyte (PCVX), Sana Biotechnology (SANA), Vericel (VCEL), Adaptive Biotechnologies (ADPT), Valneva (VALN), REGENXBIO (RGNX), Kymera Therapeutics (KYMR), Alector (ALEC), Replimune Group (REPL) and Editas Medicine (EDIT). View all of AERI's competitors. What other stocks do shareholders of Aerie Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include (CGC), Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo (WFC) and Alibaba Group (BABA). What is Aerie Pharmaceuticals' stock symbol? Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI." How do I buy shares of Aerie Pharmaceuticals? Shares of AERI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aerie Pharmaceuticals' stock price today? One share of AERI stock can currently be purchased for approximately $8.36. How much money does Aerie Pharmaceuticals make? Aerie Pharmaceuticals (NASDAQ:AERI) has a market capitalization of $406.49 million and generates $194.13 million in revenue each year. The company earns $-74.81 million in net income (profit) each year or ($1.50) on an earnings per share basis. How many employees does Aerie Pharmaceuticals have? Aerie Pharmaceuticals employs 376 workers across the globe. How can I contact Aerie Pharmaceuticals? Aerie Pharmaceuticals' mailing address is 4301 Emperor Boulevard Suite 400, North Carolina NC, 27703. The official website for Aerie Pharmaceuticals is www.aeriepharma.com. The company can be reached via phone at (919) 237-5300, via email at [email protected], or via fax at 949-526-8787. This page (NASDAQ:AERI) was last updated on 7/2/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
